Nigerian Covid-19 variant ‘could be resistant to vaccines’
6 years ago(FILES) In this file photo taken on December 15, 2020, Rocky Mountain Regional VA Medical Center investigational pharmacy technician Sara Berech prepares a dose of the Johnson & Johnson COVID-19 vaccine for a clinical trial in Aurora, Colorado. - Johnson & Johnson's single-shot Covid-19 vaccine has an overall efficacy of 66 percent, the company announced on January 29, 2021, following results from a phase 3 trial of almost 44,000 people across many countries. The figure however was as high as 72 percent in the United States but went down to 57 percent in South Africa, where a more transmissible variant is dominant. (Photo by Michael Ciaglo / GETTY IMAGES NORTH AMERICA / AFP)
A variant of coronavirus acclaimed to have been initially detected in Nigeria contains a number of mutations that are disturbing, a report shows. The report by researchers at the University…